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Conventional and intravenous immunoglobulin therapy in
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Chorea is one of the non-thrombotic neurological
complications associated with antiphospholipid
antibodies (aPL) and it is the most common
motor disorder associated with autoimmune
disease both in adult and paediatric populations.1–3
It is characterized by involuntary, aimless, rapid,
non-stereotyped movements involving mainly face
and limb muscles; psychiatric symptoms such as
emotional lability or obsessive-compulsive behav-
iour could also be present.4
Chorea may occur in the context of central
nervous system infections (herpes simplex virus,
varicella zoster virus, mycoplasma) and other
diseases of different aetiologies (neurodegenerative,
metabolic, genetic, vascular, endocrinological and
toxic).5
Sydenham’s chorea (SC) caused by streptococcal
infection is the most prevalent form of acquired
chorea in childrenbetween theagesof5and15years,4
though chorea may also be a neurological complica-
tion of systemic lupus erythematosus (SLE) and is
strongly correlatedwithaPLpositivity.1,6
Chorea has been described in association with
primary antiphospholipid syndrome (APS,
Hughes’ syndrome) in a number of patients, many
of whom were children.2,3 In recent years APS has
been increasingly recognized in various underlying
paediatric autoimmune and non-autoimmune dis-
eases.7 The diagnostic criteria of paediatric APS
are the same as in adult patients, excluding recur-
rent fetal losses,2 and do not take into account
patients presenting aPL-related non-thrombotic
clinical manifestations that are common in the
paediatric population, especially in underlying
autoimmune disease.8
It is known that non-thrombotic complications,
in children as well as adults, can precede the onset
of APS, before the occurrence of thrombosis.9
In the Ped-APS Registry,2 of the 19% of children
presenting with associated non-thrombotic clinical
manifestation at the time of the initial thrombotic
events, 7% had migraine, 4% chorea, 3% epilepsy
and 1% mood disorder. aPL may produce neuro-
logical signs indirectly causing brain endothelial
dysfunction10 or directly damaging the white
matter and structures binding to the neuronal cell
surface of the basal ganglia, that are the cerebral
structures responsible for the movement disorder.11
In most cases chorea is a benign, self-limiting
condition lasting six to seven months and, when it
is disabling and protracted, symptomatic treatment
is useful.4 In the literature several studies are
related to the management of adult and paediatric
SC, a neurological complication of acute rheumatic
fever (ARF).
However, the common treatment both in adults
and children is based firstly on the use of symptom-
atic therapy that can improve the neurochemical
imbalance within the basal ganglia, between the
neurotransmitters dopamine and gamma-aminobu-
tyric acid (GABA), that can lead tomotor disorder.12
Dopamine receptor antagonists mainly used in chil-
dren include haloperidol, risperidone and primozide
(the last one used in children 12 years or older).
Haloperidol is the first-line therapy used in
children at a dose of 0.025mg/kg/day in divided
doses up toamaximumof0.15mg/kg/day.The treat-
ment should last no more than four to eight weeks to
avoid the risk of tardive dyskinesia and
Parkinsonism.12 Risperidone is also used in young
patients affected by a severe type of chorea.13 In
adult patients other atypical neuroleptics and xena-
zine could represent effective alternatives, but there
have been no controlled studies in children.14
Valproic acid (20–25mg/kg/day in two doses for 12
weeks) was considered effective and safe in the
treatment of chorea, especially in severe cases when
Correspondence to: Raffaele Manna, Department of Internal
Medicine, Periodic Fevers Research Centre, Clinical Autoimmunity
Unit, Catholic University of the Sacred Heart, Largo Agostino
Gemelli, 8, 00168, Rome, Italy.
Email: rmanna@rm.unicatt.it
Received 8 August 2014; accepted 12 August 2014
! The Author(s), 2014. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav 10.1177/0961203314551084
 at Universita Cattolica Sacro on January 21, 2015lup.sagepub.comDownloaded from 
haloperidol treatment has failed.13 Genel et al. com-
pared the efficacy of carbamazepine (15mg/kg/day)
with valproic acid (20–25mg/kg/day) in 24 children
affected by SC, showing no significant difference
between the groups in term of clinical improvement,
time to remission and recurrence rates.15
The presence of antibodies against neuronal cell
surface in patients affected by SC or other chorea-
related autoimmune diseases, including aPL-related
chorea, suggests the possibility of using immuno-
modulant treatment in these cases.3,10 In the litera-
ture many studies reported the efficacy and the
beneficial use of corticosteroid and intravenous
immunoglobulin (IVIG) treatment in autoimmune
paediatric diseases.
Cardoso et al. first reported on the use
of immunosuppressive treatment with steroids in
SC patients resistant to conventional therapy,
suggesting that corticosteroid treatment is well tol-
erated and effective.16 Another randomized,
double-blind study evaluated 22 children affected
by SC treated with prednisone (2mg/kg/day) for
four weeks. In the following eight to 12 weeks
these patients showed a significant reduction in
chorea movements compared with a 15-patient pla-
cebo group.17 Teixera et al. first reported on the use
of intravenous methylprednisolone treatment,
followed by oral prednisone.18 Fusco et al.
showed in a four-year observational study the bene-
ficial use of intravenous methylprednisolone
(25mg/kg) in 10 patients with a paralytic form of
SC for five days, followed by oral deflazacort ther-
apy (0.9mg/kg/day).19 Although deflazacort
therapy appears to have less negative impact on
growth rate and on metabolic sequelae than
prednisone treatment, several potential severe side
effects can occur, especially in young people
(Cushing’s syndrome, hypertension, effect on
growth and weight). Also Dale et al. reported
on the use of methylprednisolone and oral prednis-
olone in young patients presenting with chorea
associated with SLE and aPL, or aPL only. In
patients resistant to corticosteroid treatment,
azathioprine, cyclophosphamide, plasma exchange
and rituximab are also used.3
In recent years IVIG therapy has been success-
fully used in young patients with severe forms of
chorea who failed to respond to conventional ther-
apy20 or have developed severe side effects
(parkinsonism and dystonia).
In the management of movement disorders asso-
ciated with aPL positivity, several different thera-
peutic strategies have been proposed, mainly in
adult patients.21–23 In the literature there are no
clinical studies on the use of IVIG in children
with aPL-related chorea. On the other hand, there
are data on the use of IVIG treatment in SC.
van Immerzeel et al. reported on two children
with SC successfully treated by IVIG (0.4 g/kg/day
for five days).20 Garvey et al. compared plasma
exchange and IVIG with prednisone in eight chil-
dren affected by SC (IVIG was used at a dose of
1 g/kg/day for two days). The authors found no
statistically significant differences between the
three groups, but clinical improvement was more
rapid and robust in the IVIG and plasma
exchange groups than in the prednisone ones.24
Walker et al. compared 10 children affected by
SC treated with standard management alone to 10
children who received IVIG, demonstrating an
improved outcome in clinical rating scales and
brain single-photon emission computed tomog-
raphy in the group treated with IVIG.25
In the literature the correlation between aPL-
related chorea and ARF is well known mainly in
adult patients, suggesting a possible overlap in
humoral and cellular autoimmunity.26,27 These
are two diseases linked by a similar pathogenic
mechanism in which the same therapeutic
approach can be considered.
Recently we reported for the first time clinical
details of two children presenting with aPL-related
chorea during streptococcal and varicella infec-
tion.28 Both cases underwent cranial and medulla
magnetic resonance imaging (MRI) with negative
results and a detailed immunological assessment
that excluded SLE and other autoimmune diseases.
In the first case only antinuclear antibodies (ANA)
were found to be positive and lupus anticoagulant
was positive several months after the acute phase
with transient positivity in the following assess-
ments. In the second case anti-b2 glycoprotein
IgM and ANA were found to be positive. Both
children failed to respond to conventional therapy
(haloperidol, valproic acid, oral corticosteroids),
and dramatically improved within one month
after the first IVIG treatment with a complete reso-
lution of the chorea one month after the second
IVIG treatment. There were no side effects and
both girls have a good tolerance.
Although the mechanism by which the IVIG acts
isn’t known, a possible involvement of B cell
lymphocytes can inactivate antineuronal antibodies
in patients affected by SC and in other autoimmune
diseases with chorea3 by an anti-idiotype network,
as demonstrated in other autoimmune diseases.29
These data suggest that IVIG treatment is bene-
ficial and useful in paediatric aPL-related chorea,
and it should be considered as a treatment option
in children who do not respond to conventional
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treatment. Moreover, IVIG could be important not
only for the clinical effect but also to prevent
prothrombotic disease in APS. However, we
encourage other case reports and prospective
studies on children to allow a better evaluation in
large series and to better understand the mechanism
of efficacy of IVIG in neurological aPL
manifestations.
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